NCT06858696

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: X4 Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.

Conditions

• Hepatic Insufficiency

Interventions

Type	Name	Description
DRUG	Mavorixafor	Mavorixafor will be administered per schedule specified in the arm description.

Timeline

• Start date: 2025-02-28
• Primary completion: 2026-03-01
• Completion: 2026-04-01
• First posted: 2025-03-05
• Last updated: 2025-04-03

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study